Pipeline

Pipeline

Autifony’s pipeline includes clinical stage programmes for Schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.

Autifony has been granted Orphan Drug Designation for AUT00206 for the treatment of Fragile X Syndrome.

Therapeutic area
Compound
(Target)
Indication
Preclinical
Phase 1
Phase 2
Psychiatry
AUT00206
(Kv3.1/3.2)
Schizophrenia
Neurology
AUT00206
(Kv3.1/3.2)
Fragile X
Kv3.1
Hearing disorders
Undisclosed target
Alzheimer’s Disease

Related Content

Related News

18Dec

Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders

0 Comments
Collaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS... Read More →
10Jul

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
18May

Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
10Jan

Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
09Aug

Autifony Announces Results from Completed CLARITY-1, Phase IIa Trial of AUT00063 in Age-related Hearing Loss

0 Comments
Autifony Therapeutics Limited, which is pioneering the development of novel pharmaceutical treatments for hearing disorders and other serious disorders of... Read More →

About

Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science.

Science

Scientific publications can be found here as well as information on Voltage-gated ion channels as therapeutics targets and Kv3 ion channels.

Pipeline

Clinical stage programmes for schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator, please take… https://t.co/A1hedx6tYy 
Apr 15 reply retweet favorite 6 days ago
Autifony Therapeutic  @AutifonyLtd
Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic appro… https://t.co/xOlDJ1kTe9 
Jan 18 reply retweet favorite 3 months ago
Autifony Therapeutic  @AutifonyLtd
Autifony is currently recruiting a Junior Medicinal Chemist, the position will be based in our lab in Stevenage, fo… https://t.co/PkP9TCxUcq 
Dec 04 reply retweet favorite 5 months ago

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image